Comprehensive Genomic Profiling. Decoded by AI. Driven by Humans.
Standard cancer care relies on treating the organ. But cancer is defined by its DNA.
To fight advanced cancer, you cannot rely on trial-and-error, and you cannot rely on outdated, single-gene tests that miss the broader picture. You need the deepest possible read of your tumour's molecular architecture.
Onkommon Signature is our portfolio of world-class, ultra-deep somatic genomic tests. Competing with the world's most advanced laboratories, we utilize Next-Generation Sequencing (NGS) to analyze up to 523 genes, massive fusions, Tumor Mutational Burden (TMB), and Microsatellite Instability (MSI) from either a solid tissue block or a simple blood draw (ctDNA).
Every Signature test is powered by our proprietary Artificial Intelligence engine, signed off by a Medical Oncologist, and mapped directly to Indian drug accessibility. Crucially, every test is bundled with 3 months of Blueprint Care to ensure your clinical team actually executes the findings.
World-class genomic intelligence, delivered for India.
Every Signature test is powered by AI, signed off by a Medical Oncologist, and mapped directly to Indian drug accessibility.
- Ultra-Deep NGS: >20,000X pre-UMI sequencing depth
- AI-Powered VUS Annotation: We don't ignore uncertainty
- Pharmacogenomics Overlay: Precision dosing for your body
- 3 Months of Blueprint Care: Execution bundled in
- KCCIRC Tumour Board: In-person review included
What is tumour (somatic) profiling?
What many people call "cancer genetic testing" is clinically known as tumour (or somatic) genomic testing. Rather than looking at the DNA you inherited from your parents (germline), our Signature tests sequence the DNA directly from your cancer cells.
Who these tests are designed for
- People with a confirmed cancer diagnosis (Stage I-IV).
- Patients looking for targeted therapies, immunotherapies, or clinical trials when standard treatments fail.
- Patients who need a rapid, real-time snapshot of their cancer via a Liquid Biopsy (blood draw) when surgery is too risky or tissue is unavailable.
- Leukaemia patients needing ultra-fast (7-day) stratification to begin immediate, targeted treatment.
What they are NOT
- Not for cancer screening in healthy individuals.
- Not for determining hereditary/family risk (Please see our Heritage panels for this).
How we compete globally.
Standard labs run a machine and give you a spreadsheet. Onkommon delivers an advanced computational war plan, built on world-class technical specifications.
Ultra-Deep NGS Sequencing
Our liquid biopsies are performed to a massive minimum depth of >20,000X (pre-UMI) and compressed to >2,000X (post-UMI). This allows us to detect incredibly rare circulating tumour DNA (ctDNA) fragments at a Variant Allele Frequency (VAF) of less than 0.1%.
>20,000X depthOvercoming Tumour Heterogeneity
A standard tissue biopsy only tests one tiny slice of a tumour. Our advanced Liquid Biopsies capture shedding DNA from the entire tumour body in the bloodstream, giving your oncologist a complete, real-time view of the cancer's complexity.
Real-time snapshotThe AI Annotation Pipeline
We utilize advanced machine learning to filter noise, deeply annotate Variants of Uncertain Significance (VUS), and cross-reference your specific mutations against millions of global clinical trial outcomes and the latest NCCN/ASCO guidelines.
AI-poweredPharmacogenomics Overlay
We don't just look at the tumour; we look at the host. We analyze how your specific liver enzymes will metabolize the recommended cancer drugs, helping your doctor adjust the dosage perfectly to prevent severe toxicity.
Precision dosingChoose your Signature panel.
We offer a complete suite of highly specialized tests tailored to your exact clinical urgency, cancer type, and sample availability.
When a tissue biopsy is unavailable, too risky, or you need to capture the most current, real-time molecular fingerprint of the cancer.
Signature Complete CGP
- Includes KCCIRC Tumour Board review
- Active trial enrolment handling
- Comprehensive fusion detection
Signature Baseline
- Required for Sentinel monitoring
- Complete molecular fingerprint
Signature Targeted
- Rapid turnaround
- India-approved drug matching only
When you already have a recent, high-quality tissue sample and need the deepest read of the tumour's physical architecture.
Signature Tissue Full
- Comprehensive MSI and TMB analysis
- No re-biopsy required
- Definitive first-line decision support
In Leukaemia and Lymphoma, decisions must be made in days, not weeks. The wrong protocol costs lives.
Signature AML Stratification
Signature ALL Stratification
After surgery, the PET scan might look "clear." But imaging cannot detect cancer smaller than 1 centimetre. These highly sensitive tests detect 1 single cancer cell in 100,000.
Signature Clear (Solid Tumour MRD)
Signature Clear (Blood Cancer MRD)
Signature panels at a glance.
Quickly compare our Solid Tumour and Haematology panels to find the right test for your situation.
| Feature | Signature Complete CGP | Signature Baseline | Signature Targeted | Signature Tissue Full |
|---|---|---|---|---|
| Sample Type | Blood (ctDNA) | Blood (ctDNA) | Blood (ctDNA) | FFPE Tissue Block |
| Genes Sequenced | 523 Genes | 118 Genes | 16 Genes | 177 Genes |
| Tumour Mutational Burden (TMB) | ✓ | ✓ | — | ✓ |
| Microsatellite Instability (MSI) | ✓ | ✓ | — | ✓ |
| Fusions | Comprehensive | 15 Genes | Targeted | Comprehensive |
| Enables Sentinel Monitoring | ✓ | ✓ (Required) | — | — (Requires Blood Baseline) |
| Best Used For | Stage 4 / Refractory | Pre-Treatment Baseline | Urgent Drug Match | First-Line Definitive |
| Price | ₹7,00,000 | ₹2,50,000 | ₹1,50,000 | ₹3,00,000 |
| Feature | Signature AML | Signature ALL | Signature Clear (Solid) | Signature Clear (Blood) |
|---|---|---|---|---|
| Cancer Type | Acute Myeloid Leukaemia | Acute Lymphoblastic Leukaemia | All Solid Tumours | Leukaemia/Lymphoma/Myeloma |
| Sample Type | Blood / Bone Marrow | Blood / Bone Marrow | Blood | Blood / Bone Marrow |
| Primary Goal | ELN Risk & Drug Eligibility | Subtype (Ph+) Classification | Post-Surgery Remission Check | Post-Treatment Remission Check |
| Turnaround Time | 7 Days (Critical TAT) | 7 Days (Critical TAT) | Standard | Standard |
| Sensitivity | High-Depth Profiling | High-Depth Profiling | 1 Cell in 100,000 | Single-Cell Level |
| Price | ₹1,50,000 | ₹1,50,000 | ₹2,50,000 | ₹2,50,000 |
Clinically validated biomarkers.
We go beyond simple gene mutations. Our advanced platforms measure complex genomic signatures that are critical for modern immunotherapies and targeted combinations.
Circulating Tumour DNA (ctDNA)
The extraction of ctDNA from a simple blood sample is recognized by international clinical guidelines (including ESMO and NCCN) as a highly valid method to identify actionable mutations without invasive surgery.
Microsatellite Instability (MSI)
A critical feature of how DNA repairs itself. Peer-reviewed research establishes MSI as a definitive predictive biomarker for cancer immunotherapy. It tells your oncologist if your immune system can be effectively stimulated to attack the tumour.
Tumour Mutational Burden (TMB)
Measures the total number of mutations present in your cancer cells. Massive pan-tumour studies have shown that a high mutational burden (TMB-H) is extensively linked to improved responses to modern checkpoint inhibitor immunotherapies.
Clonal Architecture Analysis
We don't just list mutations; we map the "trunk" (dominant driver mutations) versus the "branches" (secondary mutations). This ensures your oncologist doesn't waste time targeting a minor branch when they need to strike at the root cause of the cancer's aggressive growth.
Demystifying cancer genomics.
Empower yourself with knowledge. Watch our expert clinical team explain the science behind precision oncology.
Video Placeholder
What is a Liquid Biopsy (ctDNA) and Why Do We Use It?
Learn how a simple blood draw captures the real-time living biology of a tumour, overcoming the limitations of a standard tissue block.
Video Placeholder
The Limits of Standard Chemotherapy vs. Targeted Therapies
Why finding the specific genetic driver mutation changes the entire treatment landscape and prevents toxic, ineffective treatments.
Video Placeholder
Understanding TMB and MSI for Immunotherapy
Our Precision Oncologist explains how these two critical biomarkers unlock next-generation immunotherapy treatments.
Lab excellence & compliance.
Your clinical data is a matter of life and death. We operate strictly within the highest global standards.
CAP Accredited
Our testing utilizes laboratories accredited by the College of American Pathologists (CAP), the gold standard in global laboratory quality assurance.
Analytical Validation
100% sensitivity and specificity for SNVs and InDels, and >98% sensitivity for fusions at >3 spanning reads.
Medical Oncologist Sign-Off
No Signature report is generated by a machine and emailed blindly. Every single report is reviewed and officially signed off by an empanelled Medical Oncologist.
ICMR Compliance
All testing, data privacy, and sample handling are conducted in strict compliance with the Indian Council of Medical Research (ICMR) guidelines.
Disclaimer: Signature genomic tests are intended for use by healthcare professionals for the qualitative identification of somatic variants. The output is a clinical intelligence report highlighting potential therapies; it is not intended to be used as the sole basis for treatment decisions without the consultation of your treating physician.
KCCIRC Clinic Wing
While Onkommon Signature Panels provide your current treating doctor with the deepest molecular intelligence, we understand that sometimes you need a completely new medical perspective.
If you require a formal, medical second opinion from a licensed oncologist, Onkommon is proud to partner directly with the KCCIRC Clinic Wing.
Once your Signature report is generated, you can choose to seamlessly transition your case to the KCCIRC multidisciplinary tumour board for a formal clinical review and a direct treatment prescription based on your new genomic findings.
Please note: A formal medical consultation with KCCIRC doctors is a separate clinical service billed in addition to your Signature test.
KCCIRC Multidisciplinary Tumour Board
Led by senior oncologists, our tumour board reviews complex cases with the full weight of computational genomics and clinical expertise — delivering a formal written opinion you can trust.
Delhi & SikkimFrequently Asked Questions
Everything you need to know about Signature Molecular Profiling.
A genomic report is useless if you cannot afford the drugs or navigate the hospital system. When you purchase a Signature test, your dedicated Care Coordinator automatically takes over, filing Patient Assistance Programs (PAPs) for the drugs identified in your report and hunting for trials to execute the plan.
Not always. If you have an existing, recent tissue block from a previous surgery or biopsy, we can use our Signature Tissue Full panel. If you do not have tissue available, or if a new biopsy is too dangerous, we use our highly advanced Liquid Biopsies (like the Signature Baseline or Complete CGP), which only require a simple blood draw.
A tissue test (biopsy) tests a physical piece of the tumour from a specific point in time. A liquid biopsy tests the tumour DNA (ctDNA) that is actively shedding into your bloodstream right now. Liquid biopsies are excellent for capturing the current state of the cancer and avoiding invasive surgeries.
In haematological malignancies like Acute Myeloid Leukaemia (AML) and Acute Lymphoblastic Leukaemia (ALL), the cancer acts incredibly fast. A patient's entire treatment induction protocol is decided by their genetic subtype. We fast-track these specific panels to a 7-day turnaround because waiting 3 weeks for a standard panel is clinically unacceptable.
Signature tests are designed to look at the tumour's mutations (somatic), not your inherited DNA. However, if a Signature panel accidentally uncovers a mutation that looks like it might be inherited (germline), it triggers an immediate alert. You will be advised to seamlessly transition into our Heritage germline testing program with a Genetic Counsellor to confirm the risk for your family.